Peer-reviewed veterinary case report
Feline histiocytic tumors and treatment responses in cats
By Treggiari, E et al.·Published in Veterinary and comparative oncology·2017·Small Animal Teaching Hospital, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical outcome, PDGFRβ and KIT expression in feline histiocytic disorders: a multicentre study.
- Species:
- cat
Plain-English summary
A 5-year-old cat with a type of cancer called histiocytic sarcoma was treated for this serious condition. The cat received a combination of medications, including tyrosine kinase inhibitors and lomustine, along with radiotherapy. Some treatments showed partial success, helping to control the disease for a time, but the overall survival was shorter for cats with more severe forms of the disease. Researchers found that a specific protein (PDGFRβ) might be a target for future treatments, but more studies are needed to explore other options.
People also search for: cat histiocytic sarcoma treatment · feline cancer survival rates · tyrosine kinase inhibitors for cats
Abstract
Information about histiocytic disease in cats is limited. The aim of this study was to document clinical findings and outcome in feline histiocytic disorders, and characterize the expression of PDGFRβ and KIT in order to identify potential treatment targets. Morphologically diagnosed feline histiocytic tumours were reviewed and characterized by immunohistochemistry (IHC). Five cases of feline progressive histiocytosis (FPH), eight histiocytic sarcomas (HS) and two haemophagocytic histiocytic sarcomas (HaeHS) were confirmed. PDGFRβ was variably positive in most histiocytic cases, while KIT was negative in all. Clinical presentation, treatment and outcome were also evaluated. Partial responses were recorded in measurable disease with tyrosine kinase inhibitors and lomustine, and radiotherapy achieved long-term control in some cases. Survival times were shortest in HaeHS and disseminated disease. PDGFRβ, but not KIT, may represent a therapeutic target in feline histiocytic disorders but more studies are needed to investigate other potential treatment targets.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25665137/